VRCA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Verrica Pharmaceuticals Inc (VRCA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive trading signals, weak financial performance, and absence of significant catalysts make it prudent to hold off on investing in this stock right now.
The MACD is positive at 0.122, indicating a bullish momentum, but it is contracting. RSI is at 72.981, which is in the neutral zone, not signaling overbought or oversold conditions. The moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 6.605) in the pre-market, suggesting limited upside in the short term.
NULL identified. No recent news or significant insider/hedge fund activity. AI Stock Picker and SwingMax signals are absent.
The stock has a 60% chance of declining -2.41% in the next day and -2.23% in the next week, based on candlestick pattern analysis. Financial performance shows a significant drop in net income (-50.17% YoY) and EPS (-76.25% YoY). Gross margin has also declined drastically (-188.74% YoY).
In Q4 2025, revenue increased significantly by 1380.23% YoY to $5,092,000. However, net income dropped to -$8,074,000 (-50.17% YoY), EPS fell to -0.57 (-76.25% YoY), and gross margin dropped to 72.49 (-188.74% YoY). While revenue growth is impressive, profitability metrics are concerning.
No recent analyst rating or price target changes available.
